Cite

    Andrew Moe et al.. “A phase I open label dose‐escalation study to evaluate the tolerability, safety and immunological efficacy of sub‐urothelial durvalumab injection in adults with muscle‐invasive or high‐risk non‐muscle‐invasive bladder cancer (SUBDUE‐1, SUB‐urothelial DUrvalumab injection‐1 study): clinical trial protocol.” BJU international, vol. 128, 2021, pp. 9–17. http://access.bl.uk/ark:/81055/vdc_100144250348.0x000018